Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 November 2026
Safety Classified by Officially
CVMP opinions on veterinary medicinal products
Further to the re-examination of the opinion adopted by the Committee during its June 2026 meeting, the Committee adopted a positive opinion for a marketing authorisation for Scovella (velagliflozin), intended for the reduction of hyperinsulinaemia and reduction of associated risk of laminitis in horses with Equine Metabolic Syndrome not responsive to changes in husbandry and exercise regimen. Scovella is the first veterinary medicinal product recommended by the Committee under the limited market regulatory framework, since Regulation (EU) 2019/6 came into effect in 2022. This framework permits to grant authorisation based on customised requirements for documentation and a favourable benefit-risk assessment for a limited market authorisation.
The Committee adopted a positive opinion for a marketing authorisation for Credelio Quattro (lotilaner/moxidectin/pyrantel/praziquantel)for the treatment of mixed external and internal parasitic infestations/infections by ectoparasites, cestodes and nematodes in dogs. The veterinary medicinal product is only indicated when use against ectoparasites, cestodes and nematodes is indicated at the same time.
The Committee adopted a positive opinion for a marketing authorisation for Laverdia (verdinexor) for increasing time to progression in dogs with stage II, III and IV lymphoma where use in a home setting is indicated, a product classified as minor use, minor species/limited market in accordance with the applicable legal basis of this marketing authorisation application.
The Committee adopted a positive opinion for a marketing authorisation for Streptoporc, for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs, mortality, bacterial load and pathological lesions in serosae, joints and organs which are associated with Streptococcus suis belonging to IdeSsuis genotype 1.1.
This is an extract. The publication continues at the source.
Source: European Medicines Agency.
Read the original at the source: https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-products-cvmp-3-5-november-2026
Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- European Medicines Agency — imported from official source
- Official source
- https://www.ema.europa.eu/en/news.xml RSS
- Imported
- November 06, 2026 14:00
- Versions
- 1 recorded
- Identity
-
https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-pro...